Evaxion Biotech analyst ratings
Evaxion Biotech analyst ratings
Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
---|---|---|---|---|---|
07/18/2022 | 545.16% | Oppenheimer | → $16 | Assumes | → Outperform |
03/02/2021 | 625.81% | Oppenheimer | → $18 | Initiates Coverage On | → Outperform |
日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
---|---|---|---|---|---|
07/18/2022 | 545.16% | 奥本海默 | → 16 美元 | 假设 | → 跑赢大盘 |
2021 年 2 月 3 日 | 625.81% | 奥本海默 | → 18 美元 | 启动覆盖范围开启 | → 跑赢大盘 |
Evaxion Biotech Questions & Answers
Evaxion 生物技术问题与解答
The latest price target for Evaxion Biotech (NASDAQ: EVAX) was reported by Oppenheimer on July 18, 2022. The analyst firm set a price target for $16.00 expecting EVAX to rise to within 12 months (a possible 545.16% upside). 1 analyst firms have reported ratings in the last year.
奥本海默于2022年7月18日公布了Evaxion Biotech(纳斯达克股票代码:EVAX)的最新目标股价。该分析公司将目标股价定为16.00美元,预计EVAX将在12个月内升至12个月内(可能上涨545.16%)。1家分析公司去年公布了评级。
The latest analyst rating for Evaxion Biotech (NASDAQ: EVAX) was provided by Oppenheimer, and Evaxion Biotech their outperform rating.
奥本海默对Evaxion Biotech(纳斯达克股票代码:EVAX)的最新分析师评级由奥本海默提供,而Evaxion Biotech则提供了跑赢大盘的评级。
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Evaxion Biotech, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Evaxion Biotech was filed on July 18, 2022 so you should expect the next rating to be made available sometime around July 18, 2023.
分析师在进行了广泛的研究后得出了股票评级,其中包括浏览公开财务报表,与Evaxion Biotech的高管和客户交谈,以及听取财报电话会议。大多数分析师每三个月做一次这样的评级,因此每家公司每年应该获得4次评级。Evaxion Biotech的最新评级是在2022年7月18日发布的,因此您应该预计下一个评级将在2023年7月18日左右公布。
While ratings are subjective and will change, the latest Evaxion Biotech (EVAX) rating was a with a price target of $0.00 to $16.00. The current price Evaxion Biotech (EVAX) is trading at is $2.48, which is within the analyst's predicted range.
尽管评级是主观的,并且会发生变化,但最新的Evaxion Biotech(EVAX)评级为A,目标股价为0.00美元至16.00美元。Evaxion Biotech(EVAX)目前的交易价格为2.48美元,在分析师的预测区间内。